Initial Safety Results for Phase 2 MagnetisMM-3 Trial Presented at ASCO 2022

Dr. Alexander M. Lesokhin (Memorial Sloan Kettering Cancer Center—New York, NY) discusses initial safety results for MagnetisMM-3: Phase 2 Trial of elranatamab (BCMA)-CD3 bispecific antibody in RRMM patients. #asco2022

What is the purpose of this trial?

MagnetisMM-3 is an open-label, multicenter, non-randomized, phase 2 study to evaluate the safety and efficacy of elranatamab monotherapy in relapsed/refractory multiple myeloma (RRMM) patients. Initial safety results are presented.

The purpose of the study is to evaluate whether single-agent elranatamab (PF-06863135) can provide clinical benefit in participants with relapsed/refractory multiple myeloma. Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and B cell maturation antigen (BCMA)-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.

Conclusion:

Preliminary results of MagnetisMM-3 in RRMM patients with no prior BCMA-targeted treatment suggest that 76 mg QW elranatamab with a 2-step-up priming regimen is well tolerated, with no Grade ≥3 cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed.

Clinical trial information: NCT04649359

Doctor Bio:

Dr. Alexander M. Lesokhin is a Hematologic Oncologist at Memorial Sloan Kettering Cancer Center in New York, NY. His clinical expertise is in multiple myeloma and immunotherapy.

_______________
Improving Lives | Finding the Cure

In the United States, an estimated 32,270 new multiple myeloma cases will be diagnosed in 2021. 159,985 new myeloma cases are diagnosed yearly.

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel:    / imfmyeloma  

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma |   / myeloma  
Twitter: @IMFMyeloma |   / imfmyeloma  
Instagram: @imfmyeloma |   / imfmyeloma  
LinkedIn:   / international-myeloma-foundation  

Support the IMF! http://bit.ly/WskQHC
Category
Nonprofits & Activism
License
Standard YouTube License

In most cases, captions are autogenerated by YouTube.